Nicergoline is 1,6-dimethyl-8β-(5-bromonicotinoyl-oxymethyl)-10-α-methoxy-ergoline.
Sermion produces arteriolar vasodilatation both by a direct vascular mechanism and by changes in tissue metabolism. Sermion acts at cerebral level, increasing arterial flow and consumption of oxygen and glucose, reducing the vascular resistance; at level of pulmonary vessels reducing the resistances on the circulation of the limbs inducing vasodilatation particularly evident in subjects with insufficient flow due to arteriopathies. The systemic arterial pressure of normal or hypotensive subjects does not appear to be influenced by an average dose of the drug. In hypertensive cases, the fall in pressure values is not sudden but gradual even after IV perfusion causing no dangerous pressure change which is undesirable in presenile subjects, particularly for its consequences on the cerebral circulation. Sermion administration does not exert any unfavorable action on the heart. At the recommended dosage, the drug is devoid of toxic effects, particularly of emetic action. This side effect is absent also at higher dosage.
Acute or chronic, peripheral and cerebral vasculo-metabolic disorders with signs and symptoms of cerebral insufficiency or dementia eg, impaired memory and concentration, dizziness, depressed mood, impaired self-care, impaired sleepwalking cycle, disorientation in time and place, tinnitus, blurred vision, performance insufficiency, headache and fatigue (also those due to cerebral thrombosis, cerebral embolism, cerebral arteriosclerosis in its different manifestations). Obliterative arteriopathies of the limbs: Raynaud's syndrome and all syndromes due to altered peripheral flow. Headache, in geriatric arteriosclerotic subjects. As an adjuvant to therapy of arterial hypertension and, parenterally, of hypertensive crises.
Signs and symptoms of mental deterioration eg, cognitive, affective, behavioral and somatic disturbances associated w/ cerebral deterioration (chronic cerebrovascular insufficiency and/or senile and presenile dementia, Parkinson's disease); impaired memory, decreased vigilance and impaired concentration, mood depression, apathy, interpersonal relationships, lack of self-care, asthenia, anorexia, tinnitus, dizziness. As a coadjuvant in the rehabilitative treatment of hemiplegic patients with ictus sequelae.
Orally 30 mg twice daily.
Dementia: Orally 30 mg twice daily (60 mg/day).
Hypersensitivity to nicergoline.
Caution should be used in administering Sermion in patients with hyperuricemia or with a history of gout and/or under treatment with drugs that might be able to interfere with the metabolism and excretion of uric acid.
Sermion may potentiate the effect of antihypertensive drugs.
Use in Pregnancy: Although nicergoline has shown no teratogenic activity in toxicological studies, it is recommended to use the drug in pregnancy only if strictly necessary.
In very rare cases, clinically irrelevant side effects were noted: Hypotension and dizziness, very slight gastric distress, flushing, sleepiness and insomnia.
C04AE02 - nicergoline ; Belongs to the class of ergot alkaloids. Used as peripheral vasodilators.
Sermion sugar-coated tab 10 mg
50's
Sermion sugar-coated tab 30 mg
30's
Sign Out
